MedTrace Logo

Evaluation of the SRI B. Anthracis Lethal Factor Diagnostic System

NCT05672875 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 343

Last updated 2023-11-30

No results posted yet for this study

Summary

This study is intended to estimate the Anthrax LF Dx System specificity. Sensitivity will be estimated with 10% of the samples spiked with recombinant Bacillus anthracis lethal factor (LF) used to prepare contrived positive samples.

Conditions

  • Anthrax

Interventions

DIAGNOSTIC_TEST

Anthrax LF Dx System

Lateral flow immunoassay for the detection of the LF biomarker in whole blood samples.

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-23
Primary Completion
2023-04-20
Completion
2023-04-20
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05672875 on ClinicalTrials.gov